Minute Insight: Insulet Launches Omnipod 5 US-Wide Following Trial Period
After six months, the Omnipod 5 has seen its limited market launch expanded to cover the entirety of the US market.
You may also be interested in...
Bloomberg reported on 23 May that Dexcom is considering acquiring Insulet to become a diabetes tech giant. Dexcom said on 31 May that it is not in “active discussions” about a merger with anyone right now.
Omnipod 5 is the first tubeless automated insulin delivery system compatible with Dexcom’s G6 continuous glucose monitoring system to automatically adjust insulin levels.
In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in July 2022. Data provided by Biomedtracker.